CAS: 1923833-60-6; (R)-N-(4-Chlorophenyl)-2-(Cis-4-(6-Fluoroquinolin-4-yl)Cyclohexyl)Propanamide
- 英文名称(R)-N-(4-Chlorophenyl)-2-(Cis-4-(6-Fluoroquinolin-4-yl)Cyclohexyl)Propanamide
- 中文名称顺式-(αR)-N-(4-氯苯基)-4-(6-氟-4-喹啉基)-α-甲基环己烷乙酰胺
- IUPAC名称(R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
- 其它别名1-(6-Amino-9H-Purin-9-yl)-1-Deoxy-N-Ethyl- -D-Ribofuranuronamide; Linrodostat; (R)-N-(4-Chlorophenyl)-2-((1S,4S)-4-(6-Fluoroquinolin-4-yl)Cyclohexyl)Propanamide; (R)-N-(4-Chlorophenyl)-2-((1S,4S)-
- CAS编号1923833-60-6
- MFCD编号:MFCD31729367
- FDA UNII编号:0A7729F42K
- 分子式:C24H24ClFN2O分子量:410.92
- 产品CID: 974020
- 同类组份化合物CAS1923833-60-6 (free base)2221034-29-1 (mesylate)1791396-46-7 (dimesylate )
- 产品分类有机原料 → 有机杂环化合物 → 喹啉及其衍生物
物理性质
- 沸点606.8±45.0 °C(预测)
- 密度1?+-.0.06 g/cm3(预测)
- pKa:13.80±0.70(预测)
- LogP:6.5
- 溶解性DMSO:42.0(Max Conc. mg/mL);73.75(Max Conc. Mm) Ethanol:100.0(Max Conc. mg/mL);175.59(Max Conc. Mm)
- 外观形态白色至类白色固体
- 储存条件储存在 -20°C
- 产品应用该化合物是IDO1的不可逆抑制剂,IC50为1.7纳米;它抑制人体HELA细胞和IDOL1表示HEK293(分别为IC50=1.7和1.1纳米)的HEC293细胞的九苯乙烯生产,但显示TDO表示HEC293的HEC-293电池没有重大活动(IC50 > 2000纳米).
上下游产品
4-chloro-aniline ethyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl)acetate ethyl 1,4-dioxaspiro[4,5]dec-8-ylideneacetate ethyl 1,4-dioxaspiro[4.5]dec-8-ylacetate合成工艺路线路线简述
📜2-((1S,4S)-4-(6-Fluoroquinolin-4-yl)Cyclohexyl)Propanoic Acid,对氯苯胺置于对氯苯胺体系中,化学反应生成顺式-(Alphar)-N-(4-氯苯基)-4-(6-氟-4-喹啉基)-Alpha-甲基环己烷乙酰胺
参考文献:Immunoregulatory Agents
标题:Immunoregulatory Agents
摘要:本文描述了调节氧化还原酶酶indoleamine 2,3-Dioxygenase的化合物和含有这些化合物的组合物.还提供了使用这些化合物和组合物治疗和/或预防各种疾病,障碍和病况,包括由indoleamine 2,3-Dioxygenase介导的癌症和免疫相关障碍.
海关参考信息
- 2903919090-氯苯
2912110000-甲醛
2912120000-乙醛
2933310010-吡啶 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2024350669-A1
优先权日:2022-01-07
标题 :Inhibition of kynurenine synthesis and/or signaling to treat leukemia and myelodysplasia
发明人：KOUSTENI STAVROULA; GALÃ?N-DÃ?EZ MARTA
权利人:UNIV COLUMBIA
摘要:Methods and compositions for treating leukemia involving administering a therapeutically effective amount of an inhibitor of indoleamine 2,3 dioxygenase (IDO1). The leukemia may be is acute myeloid leukemia or acute lymphoid leukemia. The inhibitor can be a small molecule such as indiximod, epacadostat, BMS-986205, navoximod, PF-0684003, KHK2455 or LY3381916 or epacadostat. The inhibitor can be used alone or in conjunctions with other chemotherapeutic agents. IDO1 can also be inhibited using a CRISP-CAS system. The inhibitor can be administered orally, intravenously, intramuscularly, topically, arterially, or subcutaneously.
专利号:WO-2023133505-A3
优先权日:2022-01-07
标题 :Inhibition of kynurenine synthesis and/or signaling to treat leukemia and myelodysplasia
专利号:EP-4460585-A2
优先权日:2022-01-07
标 题:Inhibition of kynurenine synthesis and/or signaling to treat leukemia and myelodysplasia
专利号:WO-2024115549-A1
优先权日:2022-11-30
标题:Aryl- and heteroaryl-sulfonamide derivatives as ccr8 modulators
发明人：AISSAOUI HAMED; CORMINBOEUF OLIVIER; DIETHELM STEFAN; REMEN LUBOS; RICHARD-BILDSTEIN SYLVIA
权利人:IDORSIA PHARMACEUTICALS LTD
摘要:The present invention relates to compounds of Formula (I), their synthesis and use as CCR8 receptor modulators in medicine.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Yuan L, Huang C, Liu-Kreyche P, Voronin K, Fancher RM, Allentoff A, Zheng N, Iyer R, Zhu L, Pillutla R, Ji QC. A convenient strategy to overcome interference in LC-MS/MS analysis: Application in a microdose absolute bioavailability study. J Pharm Biomed Anal. 2018 Dec 10;165:198-206. doi: 10.1016/j.jpba.2018.12.014. [Epub ahead of print] doi: 10.1021/jacs.8b07994. Epub 2018 Oct 24. doi: 10.18632/oncotarget.25720. eCollection 2018 Jul 20.
4: Cheong JE, Ekkati A, Sun L. A patent review of IDO1 inhibitors for cancer. Expert Opin Ther Pat. 2018 Apr;28(4):317-330. doi: 10.1080/13543776.2018.1441290. Epub 2018 Feb 23. Review. doi: 10.1158/2159-8290.CD-NB2017-167. Epub 2017 Nov 22.
合成参考文献
参考文献:10.1021/acsmedchemlett.0c00195
摘要:Pu Q, Zhang H, Guo L, Cheng M, Doty AC, Ferguson H, Fradera X, Lesburg CA, McGowan MA, Miller JR, Geda P, Song X, Otte K, Sciammetta N, Solban N, Yu W, Sloman DL, Zhou H, Lammens A, Neumann L, Bennett DJ, Pasternak A, Han Y. Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors. ACS Med. Chem. Lett. 2020 Jul 15;11(8):1548–54. doi: 10.1021/acsmedchemlett.0c00195.
📝 需求与反馈
尽可能描述清楚需求与问题信息
